The Psychiatric drug development landscape is at an inflection point, with emerging mechanisms and innovative technologies promising to shape the future of Psychiatric therapeutics.
We are pleased to invite you to our exclusive Beacon Psychiatric fireside chat, where we’ll explore the scientific advancements driving the next wave of innovation, with one of the fields leading voices, Dr. Jacinthe Gingras, Chief Scientific Officer at Perpetual Bio.
This thought-provoking session will uncover which mechanisms and technologies look set to transform Psychiatric drug development in 2026 and beyond.
Key Insights:
- Schizophrenia: Discover life beyond dopamine, as we discuss non-dopamine anti-psychotics.
- Depression: Novel mechanisms of action, including the benefits of targeting NMDA receptor signaling.
- PTSD & Stress Disorders: The opportunities and challenges for psychedelic-based therapies.
- Addiction: The potential of GLP-1 as a novel target to treat alcohol and nicotine addiction.
- Emerging Technologies: Advancements in blood brain barrier-crossing & CNS delivery platforms, as well as the potential of digital wearables as clinical trial endpoints.
About The Speaker:
Dr. Jacinthe Gingras has 30 years’ experience in Neuroscience drug development, having built numerous Neuroscience portfolios, and led large departments in progressing therapeutic programs from early discovery through to IND approval.
This session offers a rare opportunity to hear directly from Dr. Gingras, as she explores the key advancements driving innovation in Psychiatric drug development
Webinar Leaders
Jacinthe Gingras
Chief Scientific Officer,
Perpetual Bio
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
